10-Q: Akoya Biosciences Reports First Quarter 2024 Results, Revenue Declines Amid Restructuring

Akoya Biosciences' first quarter 2024 results show a decrease in revenue and a net loss, impacted by lower instrument sales and restructuring costs.

Summary

• Akoya Biosciences reported a net loss of $23.48 million for the first quarter of 2024, compared to a net loss of $18.80 million for the same period in 2023.
• Total revenue decreased by 14% to $18.35 million, down from $21.41 million in the first quarter of 2023.
• Product revenue declined by 22% to $12.14 million, primarily due to a decrease in instrument sales, while service and other revenue increased by 6% to $6.21 million.
• The company placed 30 new instruments in the first quarter of 2024, compared to 58 in the same period of 2023.
• Gross profit decreased by 32% to $8.38 million, with a gross margin of 46%, down from 57% in the first quarter of 2023.
• Operating expenses totaled $29.96 million, including a $2.97 million impairment charge related to exiting a facility and $1.40 million in restructuring costs.
• The company's cash, cash equivalents, and marketable securities totaled $61.58 million as of March 31, 2024.
• The company has an accumulated deficit of $253.56 million as of March 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant challenges. While there are some positives like recurring revenue growth and focus on key platforms, the overall financial performance is weak with declining revenue, increased losses, and restructuring costs. The company's future outlook is uncertain, and the need for potential capital raises adds to the negative sentiment.

Positives

• Service and other revenue increased by 6%, indicating growth in lab services and companion diagnostic development.
• Recurring revenue was 54% of total revenue for the three months ended March 31, 2024, compared to 38% for the same period in 2023.
• The company is focused on increasing sales of its PhenoCycler and PhenoImager platforms.
• The company believes its existing cash, cash equivalents, and marketable securities will be adequate to satisfy its current operating plans for at least the next twelve months.

Negatives

• Total revenue decreased by 14% year-over-year.
• Product revenue decreased by 22%, primarily due to a decrease in instrument sales.
• Gross profit decreased by 32% and gross margin decreased to 46%.
• The company incurred a net loss of $23.48 million for the quarter.
• The company recorded a $2.97 million impairment charge related to exiting a facility.
• Restructuring costs of $1.40 million were incurred due to a workforce reduction.
• Instrument placements decreased from 58 in Q1 2023 to 30 in Q1 2024.

Risks

• The company has incurred losses since its inception and expects to continue to incur operating losses for the foreseeable future.
• The company's future success is dependent on its ability to successfully commercialize its products and obtain additional capital if necessary.
• The company is subject to risks including development and market acceptance of its products, competition, and protection of proprietary technology.
• The company's financial performance is impacted by the volume of instrument sales, which can fluctuate significantly from period to period.
• The company's gross profit in future periods will depend on market conditions, sales mix, and costs from contract manufacturers.
• The company's debt agreement includes financial covenants that must be met, and a default could limit the ability to obtain additional financing.

Future Outlook

The company expects to continue to incur operating losses for the foreseeable future but plans to improve results of operations in an effort to achieve cash flow positivity. They also plan to continue to grow the business, market and sell new and existing solutions, invest in processes and infrastructure, support research and development, expand intellectual property, and acquire complementary businesses or technologies.

Management Comments

• The company is focused on increasing sales of its PhenoCycler and PhenoImager platforms to new and existing customers.
• The company believes that expansion of its installed base will drive an increase in recurring reagent and instrument service revenue.
• The company aims to mitigate downward pressure on average selling prices by increasing the value proposition of its instruments and consumables.
• The company believes its existing cash, cash equivalents, and marketable securities will be adequate to satisfy its current operating plans for at least the next twelve months.

Industry Context

The spatial biology market is rapidly evolving, and Akoya is positioned as a key player with its PhenoCycler and PhenoImager platforms. The company's focus on end-to-end solutions and its ability to serve the discovery, translational, and clinical markets aligns with the industry's growing demand for comprehensive spatial phenotyping tools. The company is facing increased competition and needs to continue to innovate and expand its market presence to maintain its position.

Comparison to Industry Standards

• Akoya's revenue decline in instrument sales contrasts with the overall growth trend in the life sciences tools market, where demand for advanced technologies is generally increasing.
• The company's gross margin of 46% is lower than some of its peers in the diagnostics and life sciences tools sector, which often have gross margins above 60%.
• The company's operating expenses, particularly the restructuring and impairment charges, are higher than industry averages, indicating challenges in cost management.
• Compared to companies like NanoString Technologies and 10x Genomics, Akoya's instrument placement numbers are lower, suggesting a need to accelerate market penetration.
• Akoya's focus on spatial biology is a key differentiator, but the company needs to demonstrate consistent revenue growth and profitability to compete effectively with established players in the broader life sciences market.

Related Party Transactions

• The company incurred costs of goods sold of approximately $1.67 million related to sales of consumables manufactured by Argonaut Manufacturing Services Inc. (AMS), a related party.

Stakeholder Impact

• Shareholders are negatively impacted by the decreased revenue, increased net loss, and restructuring costs.
• Employees were impacted by the workforce reduction in January 2024.
• Customers may be impacted by the company's restructuring and changes in product offerings.
• Suppliers may be impacted by the company's cost-saving initiatives and changes in manufacturing processes.
• Creditors are impacted by the company's increased debt levels and financial performance.

Next Steps

• The company plans to continue to grow its business while improving results of operations in an effort to achieve cash flow positivity.
• The company plans to market and sell new and existing solutions and services.
• The company plans to invest in processes and infrastructure to scale its business.
• The company plans to support research and development to introduce new solutions.
• The company plans to expand, protect and defend its intellectual property.
• The company plans to acquire complementary businesses or technologies to support the growth of its business.

Key Dates

Keywords

spatial biology, phenotyping, instruments, reagents, revenue, net loss, gross profit, operating expenses, research and development, biopharma, diagnostics, clinical research